Scholars Central

OtherPublished 22 Jul 2016

Lapatinib in the management of breast cancer

Authors: Peter S Hall, Jaishree Bhosle, David A Cameron

Clinical Practice

Volume 6 · Issue 4 · Pages 553

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Lapatinib is licensed for use in combination with capecitabine for the treatment of patients with progressive advanced breast cancer whose tumors overexpress the human epidermal growth factor receptor 2 (HER2/erbB2/HER2-neu), following therapy with an anthracycline, a taxane and trastuzumab. Lapatinib targets both the epidermal growth factor receptor (EGFR/HER1/erbB1) and HER2, and represents one of the most promising of a number of pharmacological attempts to bypass resistance mechanisms to trastuzumab. Further studies are being conducted to examine the potential role of lapatinib in the management of breast cancer in both the early and advanced setting. This article evaluates the pharmacology, tolerability and clinical efficacy of lapatinib. The future roles of lapatinib in the treatment of breast cancer are also discussed.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Clinical Practice.

All its articles

Article · 28 Mar 2025

Using

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical Practice
  • SubjectGeneral & Internal Medicine
  • BylineArticles whose byline prints “Peter S Hall”
  • BylineArticles whose byline prints “Jaishree Bhosle”
  • BylineArticles whose byline prints “David A Cameron”